JP5785392B2 - 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター - Google Patents
過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター Download PDFInfo
- Publication number
- JP5785392B2 JP5785392B2 JP2010503615A JP2010503615A JP5785392B2 JP 5785392 B2 JP5785392 B2 JP 5785392B2 JP 2010503615 A JP2010503615 A JP 2010503615A JP 2010503615 A JP2010503615 A JP 2010503615A JP 5785392 B2 JP5785392 B2 JP 5785392B2
- Authority
- JP
- Japan
- Prior art keywords
- progesterone
- uterine bleeding
- administered
- treatment
- cdb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
19歳の思春期後の女性は、発熱、感染症、子宮出血、点状出血、呼吸促迫で診察を受けた。血液検査によれば、貧血(Hb:7.8g/dL)、正常な白血球数(WBC:8657cells/μL)、血小板減少(血小板:13,476cells/mm3)が特定された。骨髄生検を行ったところ、過形成骨髄が判明し、白血病性芽球の単形性浸潤および正常な骨髄成分の顕著な減少が見られた。急性リンパ性白血病と診断された。
31歳の女性は肺炎で診察を受けた。患者は、最近寝汗と体重減少があったことを報告した。胸部X線では著しい縦隔リンパ節腫大が見られ、リンパ腫の完全な評価を行った。診断は、III期のホジキン病だった。患者の症状は、化学療法(MOPP)および拡大照射が必要であることを示していた。この療法の主要なリスクは骨髄抑制である。これは、患者が重度の感染症と敗血症にかかる可能性があるために生命にかかわるが、重度の血小板減少と子宮出血を含む広汎性出血も伴うことになる。
42歳の中程度喫煙者の女性(BMI:32)は、足の深部静脈血栓症による肺塞栓症の抗凝固療法を受けた。抗凝固療法を適合させようとしたが、患者の月経は激しく(月経過多)、最長2週間続いた。患者のHbは9.2g/dLだった。経腟的超音波、子宮内膜生険、および子宮鏡検査では、患者の月経過多を引き起こす基礎症状は明らかにならなかった。
Claims (10)
- 治療有効量のCDB−2914および/またはCDB−4124の使用であって、
治療を必要とする女性における凝固障害による過剰子宮出血の治療および/または予防のための薬剤の調製における使用。 - 請求項1において、
前記凝固障害が、血友病、フォン−ウィルブランド病、肝機能障害、血小板減少症、白血病、汎発性血管内凝固、骨髄形成不全、および不適当な抗凝固治療からなる群から選択される使用。 - 請求項1において、
前記薬剤を1〜180日間にわたって投与する使用。 - 請求項1において、
前記薬剤を出血ピークまたは月経時に投与する使用。 - 請求項1において、
前記薬剤を毎日、一日おき、1週間に一度または1ヶ月に一度投与する使用。 - 請求項1において、
前記薬剤を1回の投与で投与する使用。 - 請求項1において、
CDB−2914および/またはCDB−4124を1日当たり0.1〜1000mgの用量で投与する使用。 - 請求項7において、
CDB−2914を、一日当たり5〜15mgの用量で投与する使用。 - 請求項1において、
前記薬剤を同時または順番にエストロゲンと組み合わせて投与する使用。 - 請求項1において、
前記薬剤を、腟内、直腸内、皮下、静脈内、皮内、筋肉内、腹腔内、子宮内、鼻腔内、経皮的、口腔投与または埋込型装置による投与によって投与する使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90787507P | 2007-04-20 | 2007-04-20 | |
US60/907,875 | 2007-04-20 | ||
PCT/IB2008/000945 WO2008129396A2 (en) | 2007-04-20 | 2008-04-18 | Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013173782A Division JP5804654B2 (ja) | 2007-04-20 | 2013-08-23 | 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010524915A JP2010524915A (ja) | 2010-07-22 |
JP5785392B2 true JP5785392B2 (ja) | 2015-09-30 |
Family
ID=39766931
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010503615A Expired - Fee Related JP5785392B2 (ja) | 2007-04-20 | 2008-04-18 | 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター |
JP2013173782A Expired - Fee Related JP5804654B2 (ja) | 2007-04-20 | 2013-08-23 | 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013173782A Expired - Fee Related JP5804654B2 (ja) | 2007-04-20 | 2013-08-23 | 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター |
Country Status (13)
Country | Link |
---|---|
US (2) | US8569274B2 (ja) |
EP (1) | EP2148681B1 (ja) |
JP (2) | JP5785392B2 (ja) |
CA (1) | CA2684450C (ja) |
CY (1) | CY1117586T1 (ja) |
DK (1) | DK2148681T3 (ja) |
ES (1) | ES2575554T3 (ja) |
HR (1) | HRP20160689T1 (ja) |
HU (1) | HUE029397T2 (ja) |
PL (1) | PL2148681T3 (ja) |
PT (1) | PT2148681E (ja) |
SI (1) | SI2148681T1 (ja) |
WO (1) | WO2008129396A2 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009061569A1 (en) * | 2007-11-05 | 2009-05-14 | Repros Therapeutics Inc. | Compositions and methods for treating dysfunctional uterine bleeding |
US8299050B2 (en) * | 2008-01-29 | 2012-10-30 | Laboratoire Hra-Pharma | Method for treating uterine fibroids |
TW201002736A (en) * | 2008-04-28 | 2010-01-16 | Repros Therapeutics Inc | Compositions and methods for treating progesterone-dependent conditions |
TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
US8512745B2 (en) * | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
JP5894143B2 (ja) * | 2010-03-22 | 2016-03-23 | リプロス セラピューティクス インコーポレイテッド | 抗黄体ホルモンの無毒送達のための組成物および方法 |
EP2471537A1 (en) * | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
EP2545922A1 (en) * | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
EP2822556A1 (en) * | 2012-03-07 | 2015-01-14 | Ligand Pharmaceuticals Inc. | Steroid hormone and cholesterol pathways as one unified homestatic system |
EP2641602A1 (en) * | 2012-03-23 | 2013-09-25 | PregLem S.A. | Method for treating gynecological diseases |
NZ702467A (en) | 2012-05-31 | 2016-07-29 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
CN104755087A (zh) | 2012-11-02 | 2015-07-01 | 利普生物药剂公司 | 治疗孕酮依赖性病况的方法和组合物 |
TWI669134B (zh) * | 2012-12-14 | 2019-08-21 | 法商Hra實驗製藥股份有限公司 | 銅子宮內系統 |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
EP3394079A4 (en) | 2015-12-23 | 2019-08-21 | Oric Pharmaceuticals, Inc. | INHIBITORS OF GLUCOCORTICOIDREZEPTORS |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
KR102237916B1 (ko) | 2016-10-07 | 2021-04-09 | 오릭 파마슈티칼스, 인크. | 글루코코르티코이드 수용체의 억제제 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
US5468741A (en) * | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
EP0806952B1 (de) * | 1995-02-02 | 2003-04-02 | Schering Aktiengesellschaft | Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
CA2668824A1 (en) * | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
BRPI0513141A (pt) * | 2004-07-09 | 2008-04-29 | Population Council Inc | composição para anel vaginal, e, processo de contracepção a longo prazo |
EP1809602B1 (en) * | 2004-10-27 | 2008-10-29 | Janssen Pharmaceutica N.V. | Indole derivatives useful as progesterone receptor modulators |
-
2008
- 2008-04-18 PT PT08737471T patent/PT2148681E/pt unknown
- 2008-04-18 CA CA2684450A patent/CA2684450C/en not_active Expired - Fee Related
- 2008-04-18 JP JP2010503615A patent/JP5785392B2/ja not_active Expired - Fee Related
- 2008-04-18 EP EP08737471.6A patent/EP2148681B1/en active Active
- 2008-04-18 DK DK08737471.6T patent/DK2148681T3/en active
- 2008-04-18 US US12/596,624 patent/US8569274B2/en not_active Expired - Fee Related
- 2008-04-18 WO PCT/IB2008/000945 patent/WO2008129396A2/en active Application Filing
- 2008-04-18 HU HUE08737471A patent/HUE029397T2/en unknown
- 2008-04-18 PL PL08737471.6T patent/PL2148681T3/pl unknown
- 2008-04-18 ES ES08737471.6T patent/ES2575554T3/es active Active
- 2008-04-18 SI SI200831629A patent/SI2148681T1/sl unknown
-
2013
- 2013-08-23 JP JP2013173782A patent/JP5804654B2/ja not_active Expired - Fee Related
- 2013-10-07 US US14/047,780 patent/US20150051180A9/en not_active Abandoned
-
2016
- 2016-04-15 CY CY20161100316T patent/CY1117586T1/el unknown
- 2016-06-16 HR HRP20160689TT patent/HRP20160689T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI2148681T1 (sl) | 2016-07-29 |
WO2008129396A2 (en) | 2008-10-30 |
US20100190758A1 (en) | 2010-07-29 |
PL2148681T3 (pl) | 2016-09-30 |
JP5804654B2 (ja) | 2015-11-04 |
US20150051180A9 (en) | 2015-02-19 |
ES2575554T3 (es) | 2016-06-29 |
HRP20160689T1 (hr) | 2016-07-15 |
PT2148681E (pt) | 2016-06-17 |
EP2148681B1 (en) | 2016-03-16 |
CA2684450C (en) | 2017-05-30 |
WO2008129396A3 (en) | 2009-08-13 |
CY1117586T1 (el) | 2017-04-26 |
US20140100208A1 (en) | 2014-04-10 |
JP2013253098A (ja) | 2013-12-19 |
DK2148681T3 (en) | 2016-07-04 |
US8569274B2 (en) | 2013-10-29 |
HUE029397T2 (en) | 2017-03-28 |
EP2148681A2 (en) | 2010-02-03 |
CA2684450A1 (en) | 2008-10-30 |
JP2010524915A (ja) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5785392B2 (ja) | 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター | |
TWI680773B (zh) | 具有經改善之安定性的藥學組成物(二) | |
JP2022185059A (ja) | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 | |
JP2017501154A (ja) | 低血圧治療のための単独または併用使用されるアンギオテンシンii | |
US11980604B2 (en) | Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane | |
RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
JP2022508513A (ja) | がん治療のための併用療法 | |
JP2011506436A (ja) | 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
KR20210126515A (ko) | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 | |
US20080312250A1 (en) | Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide | |
WO2024120523A1 (zh) | 一种治疗前列腺癌的药物组合及其应用 | |
WO2021224494A1 (en) | New treatments of viral infections | |
TW202245742A (zh) | 預防、治療或改善潰瘍性結腸炎的方法 | |
CN117462528A (zh) | RocA在治疗贫血中的应用 | |
JP2014169286A (ja) | 子宮筋腫に伴う子宮出血抑制用医薬 | |
CN117462542A (zh) | Aila在治疗贫血中的应用 | |
US20210085711A1 (en) | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease | |
US20030207811A1 (en) | Method of treating retinopathy of prematurity using somatostatin analogs | |
JPH07206678A (ja) | 卵管閉塞治療剤 | |
JPH02178226A (ja) | レイノー現象を伴う疾病の治療剤 | |
JP2017145242A (ja) | 重度の肝機能障害のある患者のためのルストロンボパグを含有する血小板産生促進剤 | |
US20080219946A1 (en) | Therapeutic agent and method for ovulation disorder caused by luteinized unruptured follicle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130823 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130910 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20131011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150623 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150724 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5785392 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |